Coherus Oncology (CHRS) Other Accumulated Expenses (2013 - 2026)

Coherus Oncology has disclosed Other Accumulated Expenses across 14 years of filings, most recently posting $10.9 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $10.9 million, down 5.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (down 5.0% YoY), and the FY2025 annual result was $11.3 million, down 43.81% from the prior year.
• Other Accumulated Expenses came in at $10.9 million for Q1 2026 at Coherus Oncology, down from $11.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $20.0 million in Q4 2024 to a low of $6.8 million in Q2 2025.
• The 5-year median for Other Accumulated Expenses is $11.3 million (2025), against an average of $11.8 million.
• Across the five-year window, Other Accumulated Expenses jumped 204.52% in 2022 and sank 53.52% in 2025, its largest moves.
• Coherus Oncology's Other Accumulated Expenses stood at $10.6 million in 2022, then slipped by 28.27% to $7.6 million in 2023, then surged by 162.56% to $20.0 million in 2024, then plunged by 43.81% to $11.3 million in 2025, then declined by 3.33% to $10.9 million in 2026.
• The last three Other Accumulated Expenses figures came in at $10.9 million (Q1 2026), $11.3 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.